Has the Amazon Prime of Cancer Genomic Profiling Arrived?

Posted by Pavankumar Anne on Dec 12, 2019 9:31:04 AM

Jim Adelizzi co-wrote this blog post with Pavankumar Anne.

The excitement behind precision medicine in oncology is impossible to ignore. Genomic profiling has enabled the greatest growth in precision medicine in oncology, and today there are 80-plus FDA-approved treatment options indicated for specific genetic markers. Innovations in next-generation sequencing (NGS) technology have further enabled advances in genomic profiling by increasing the speed, accuracy and affordability of sequencing. With this innovation comes a variety of options for testing:


>
Read More

Powering Up Your Oncology Patient Support Program

Posted by Rachael Pius on Nov 20, 2019 8:00:00 AM

Gila Allswang co-wrote this blog post with Rachael Pius.

As oncology patients and caregivers continue to play a more active role in their healthcare decisions and have more options available to them than ever before, many pharma companies are upping their investment in patient support programs. While patient-centered care can empower and engage patients by building their knowledge—and can often drive competitive differentiation—it’s also fraught with its own challenge: Oncology patients simply are not aware of the service offerings provided by manufacturers and are much less likely to use them. On average, only 46% of oncology patients and caregivers are aware of the offerings available to them, according to ZS’s recent survey on patient support programs. In many cases they may also find the offerings from other stakeholders in the health ecosystem to be more relevant to meet their needs. Further, oncology patients are offered support from many different players across the healthcare ecosystem—patient advocacy, specialty pharmacy, payers, hospital systems and pharmaceutical manufacturers are all offering patients support. There’s a high degree of overlap across the landscape, so it’s important for manufacturers to understand where patients are accessing support and why.


>
Read More

In the Trenches: Advice for New Patient Marketers in Oncology

Posted by Rachael Pius on Jul 29, 2019 8:00:00 AM

As many patient marketing veterans know, launching a marketing strategy for patients within oncology today is as much an exercise in agility as it is a science. Whether you’re a newly minted MBA graduate about to start a job in patient marketing or you’re rotating into the oncology patient space, you’ll quickly learn that patient marketing is a highly nuanced and fast-paced world. However, a little experience and advice can transform that “perpetual launch mode” feeling into one of excitement and promise for what’s to come for patients.


>
Read More

The Next Frontier for Biosimilars Intrusion

Posted by Will Gatziolis on Jul 25, 2019 8:00:00 AM

Eric Detwiler, Sandeep Sangwan and Christina Corridon co-wrote this blog post with Will Gatziolis.

As of mid-2019, the U.S. market has seen considerable competition from biosimilars in supportive oncology care. The next U.S. biosimilar frontier is therapeutic oncology care, where Genentech’s big trio—Rituxan, Herceptin and Avastin—will likely attempt to hold their ground against biosimilars. Reference product manufacturers and biosimilar manufacturers have been closely monitoring U.S. biosimilar uptake to understand how this market is likely to evolve, but diverse go-to-market and defense strategies may leave us with more questions than answers. As pricing pressure mounts in the U.S., so does pressure on biosimilar uptake, leaving reference product manufacturers and biosimilar manufacturers alike wondering what biosimilar uptake will look like in the therapeutic oncology space, and how much price erosion can be expected due to biosimilar competition.


>
Read More

Assessing the Next Wave of Oncology First Launches

Posted by Ben Hohn on Jul 2, 2019 11:39:30 AM

Judith Kulich, Jon Roffman, Cody Powers and Renuka Agarwal co-wrote this blog post with Ben Hohn.

The 2019 BIO International Conference, held June 3-6 in Philadelphia, attracted more than 16,000 attendees from more than 70 countries, with representation from biotechnology and pharmaceutical companies, academic institutions, regulators, investors and other organizations. The conference provided a platform for discovery and discussion, resulting in more than 41,000 partnering meetings.


>
Read More